TY - JOUR
T1 - Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease
AU - McDermott, Mary M.
AU - Liu, Kiang
AU - Ferrucci, Luigi
AU - Tian, Lu
AU - Guralnik, Jack M.
AU - Tao, Huimin
AU - Ridker, Paul M.
AU - Criqui, Michael H.
N1 - Funding Information:
This study was supported by grants R01-HL58099 , R01-HL64739 , R01-HL071223 , and R01-HL076298 from the National Heart, Lung, and Blood Institute , Bethesda, Maryland; by grant RR-00048 from the National Center for Research Resources , Bethesda, Maryland; and in part by the Intramural Research Program, National Institute on Aging , Bethesda, Maryland.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - The aim of this study was to determine whether persistently high levels of interleukin-6 (IL-6) or soluble vascular adhesion molecule1 (sVCAM-1) are associated with faster functional decline compared to fluctuating or persistently low biomarker levels in 255 participants with peripheral arterial disease. Participants underwent baseline and <2 annual follow-up measures of IL-6 and sVCAM-1. Participants were categorized as follows: category 1, annual levels of IL-6 (or sVCAM-1) were in the lowest tertile for <3 study visits; category 3, annual levels of IL-6 (or sVCAM-1) were in the highest tertile for <3 visits. Category 2 levels of IL-6 (or sVCAM-1) did not meet criteria for group 1 or 3. Six-minute walking distance, fastest paced 4-m walking velocity, and the Short Physical Performance Battery were measured annually. Results were adjusted for age, gender, race, co-morbidities, statin use, physical activity, the ankle-brachial index, and other confounders. Across IL-6 categories, average annual decreases in 6-minute walking distance were -21.4 feet in category 1, -49.2 feet in category 2, and -76.8 feet in category 3 (p for trend = 0.013), and average annual decreases in Short Physical Performance Battery score were -0.18, -0.45, and -0.62, respectively (p for trend = 0.022). Similar associations of IL-6 categories with decrease in fastest paced walking velocity were observed (p for trend = 0.034). There were no significant associations of sVCAM-1 categories with functional decline. In conclusion, in participants with peripheral arterial disease, persistently high IL-6 levels are associated with faster functional decline compared to those with fluctuating or persistently low IL-6 levels.
AB - The aim of this study was to determine whether persistently high levels of interleukin-6 (IL-6) or soluble vascular adhesion molecule1 (sVCAM-1) are associated with faster functional decline compared to fluctuating or persistently low biomarker levels in 255 participants with peripheral arterial disease. Participants underwent baseline and <2 annual follow-up measures of IL-6 and sVCAM-1. Participants were categorized as follows: category 1, annual levels of IL-6 (or sVCAM-1) were in the lowest tertile for <3 study visits; category 3, annual levels of IL-6 (or sVCAM-1) were in the highest tertile for <3 visits. Category 2 levels of IL-6 (or sVCAM-1) did not meet criteria for group 1 or 3. Six-minute walking distance, fastest paced 4-m walking velocity, and the Short Physical Performance Battery were measured annually. Results were adjusted for age, gender, race, co-morbidities, statin use, physical activity, the ankle-brachial index, and other confounders. Across IL-6 categories, average annual decreases in 6-minute walking distance were -21.4 feet in category 1, -49.2 feet in category 2, and -76.8 feet in category 3 (p for trend = 0.013), and average annual decreases in Short Physical Performance Battery score were -0.18, -0.45, and -0.62, respectively (p for trend = 0.022). Similar associations of IL-6 categories with decrease in fastest paced walking velocity were observed (p for trend = 0.034). There were no significant associations of sVCAM-1 categories with functional decline. In conclusion, in participants with peripheral arterial disease, persistently high IL-6 levels are associated with faster functional decline compared to those with fluctuating or persistently low IL-6 levels.
UR - http://www.scopus.com/inward/record.url?scp=79954601046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954601046&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2011.01.007
DO - 10.1016/j.amjcard.2011.01.007
M3 - Article
C2 - 21371679
AN - SCOPUS:79954601046
VL - 107
SP - 1392
EP - 1398
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 9
ER -